Deadline Extended: February 3, 2020
The American Society for Experimental Neurotherapeutics (ASENT) was established for leaders in academia, government, advocacy and industry who are dedicated to advancing the development of improved therapies for diseases and disorders of the nervous system. The 22nd ASENT Annual Meeting, which will take place March 2-5, 2020 at the Hyatt Regency Bethesda in Bethesda, MD, will offer participants the most current information in the field of neurotherapeutics.
All accepted abstracts will be published online in Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, unless the submitting author requests otherwise.
All submitters will receive notification of the status of their abstracts and presentations for the meeting by February 2020. All presenters are expected to cover their own travel and lodging. Presenters will receive a significantly discounted registration.
Abstracts are peer-reviewed by a committee, and all accepted abstracts will be available at the poster sessions. Authors of accepted abstracts will also be considered for a Pipeline Presentation, which is 5 minutes and 3 slides.
ASENT's Abstract Review Committee will review and make the final decision of abstract approval based on scientific merit and program considerations. ASENT requires that an author attends the Annual Meeting to present the work. If the first author is not planning to attend the Annual Meeting, then a co-author may present the work. Changes in presenter should be emailed to email@example.com and include the abstract title, ID number, and the presenter’s name.
- Abstracts can have been presented at other recent scientific meetings so long as the content is appropriate for ASENT.
- Abstracts must be submitted in English and all presentations will be in English.
- Abstracts must conform to the instructions provided for electronic submission.
For full guidelines click through REGISTER button. You can submit as a guest, however you will be charged the non-member rate.